Intravitreal bevacizumab in a patient with neovascular glaucoma
- PMID: 16583637
Intravitreal bevacizumab in a patient with neovascular glaucoma
Abstract
The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation. IOP improved within 2 days and the patient experienced marked improvement in comfort. Bevacizumab may be an effective medication for the treatment of neovascular glaucoma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical